What changed
$NVS — BUY 📊 | 6 MONTHS THESIS
🎯 latest | Rev $3.5B | EPS $1.99 vs $2.07 🔴
💡 Consensus expected EPS $2.07, actual $1.99, causing a negative reaction. However, the miss was largely due to non-recurring items; normalized earnings power remains intact and is underappreciated. The market is overly focused on the headline miss, ignoring continued revenue growth in key drugs and upcoming catalysts.
📉 Reward/risk: 2.75:1
🏢 Business Quality: 8/10 - Leading innovative pharma with strong franchise in immunology, cardiovascular, and oncology; high margins, diversified pipeline, and post-Sandoz spin focus on high-growth areas.
📊 Valuation: fair - P/E 18.5x on trailing annualized EPS, slightly above peer average but justified by superior growth profile. EV/EBITDA ~13x, FCF yield ~5%.
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/NVS0621